Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., Goldin, Jonathan, Arriola, Edgar, Strange, Charlie, Bolster, Marcy B., Seibold, James R., Riley, David J., Hsu, Vivien M., Varga, John, Schraufnagel, Dean, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fred, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark, Khanna, Dinesh, Li, Ning, Li, Gang
Formato: Artigo
Idioma:Inglês
Publicado em: American Thoracic Society 2007
Assuntos:
E. Interstitial Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2078679/
https://ncbi.nlm.nih.gov/pubmed/17717203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.200702-326OC
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados